New drug trial aims to protect kidneys from scarring disease
Disease control
Not yet recruiting
This research study is testing whether regular injections of an investigational drug called APL2 can help control focal segmental glomerulosclerosis (FSGS), a serious kidney disease that causes scarring. The study will involve about 270 adults and teenagers with FSGS to see if th…
Phase: PHASE2, PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 06, 2026 15:38 UTC